Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Trials

MRD trials

The curated index is a sourced list of studies. Accruing is the live ClinicalTrials.gov set of studies that are recruiting or not yet recruiting. DYNAMIC-III is not in the curated index because it is registered in Australia and New Zealand, not with an NCT id.

Recruiting and not-yet-recruiting studies that use ctDNA, cfDNA, or MRD in eligibility, a treatment decision, or a primary or secondary endpoint, plus observational studies focused on that testing. 1123 studies from 2267 registry records. Hematologic trials that list MRD only as a secondary endpoint are listed separately. Last synced Nov 18, 2026, 2:04 PM EST.

  • GU · ProstateRecruitingPhase 3NCT07028853

    This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

    Pfizer · 319 locations · Updated 2026-10-14

  • GU · ProstateRecruitingPhase 3NCT03903835

    ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer

    Karolinska Institutet · 32 locations · Updated 2025-04-09

  • GU · ProstateNot yet recruitingPhase 2NCT07925268

    Study of Ifinatamab Deruxtecan in De Novo or Treatment-Emergent Neuroendocrine Prostate Cancer

    Rahul Aggarwal · 1 locations · Updated 2026-11-09

  • GU · ProstateRecruitingPhase 2NCT07210086

    Phase II Non-Randomized Study Evaluating POSLUMA-PSMA PET Response After Oligo- Metastatic/Progressive-directed Treatment With Radiotherapy (PROMPT-R)

    City of Hope Medical Center · 1 locations · Updated 2026-10-29

  • GU · ProstateNot yet recruitingPhase 2NCT07723651

    [18F]Fluorthanatrace - Positron Emission Tomography (FTT-PET) and ctDNA to Predict Response to PARP Inhibitor Therapy in Metastatic Prostate Cancer (mPC)

    Washington University School of Medicine · 3 locations · Updated 2026-10-21

  • GU · ProstateRecruitingPhase 2NCT07698535

    Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial

    University of Washington · 1 locations · Updated 2026-10-19

  • GU · ProstateNot yet recruitingPhase 2NCT06836726

    Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resistant Prostate Cancer

    University Health Network, Toronto · 1 locations · Updated 2026-09-24

  • GU · ProstateRecruitingPhase 1 / Phase 2NCT07002320

    Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer

    Institute of Cancer Research, United Kingdom · 4 locations · Updated 2026-09-08

  • GU · ProstateNot yet recruitingPhase 2NCT07568756

    Utilization of Flotufolastat 18F PET for Post-Focal Therapy Prostate Cancer Evaluation

    University of California, Irvine · 1 locations · Updated 2026-05-06

  • GU · ProstateRecruitingPhase 1 / Phase 2NCT06615752

    Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients

    Charles Drew University of Medicine and Science · 1 locations · Updated 2026-04-15

  • GU · ProstateRecruitingPhase 2NCT06305832

    Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer

    The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · 2 locations · Updated 2024-03-12

  • GU · ProstateRecruitingPhase 2NCT06259123

    Neoadjuvant PSMA-RLT in Oligometastatic PCa

    Medical University of Vienna · 1 locations · Updated 2024-02-15

  • GU · ProstateRecruitingPhase 2NCT06220188

    PSMA-RLT in Biochemically Recurrent PCa

    Medical University of Vienna · 1 locations · Updated 2024-02-13

  • GU · ProstateRecruitingNot reportedObservationalNCT00923221

    Collection of Blood From Patients With Prostate Cancer

    National Cancer Institute (NCI) · 1 locations · Updated 2026-11-12

  • GU · ProstateRecruitingNot reportedObservationalNCT07222436

    Circulating Tumor DNA in High Risk Localized Prostate Cancer

    University of Pittsburgh · 1 locations · Updated 2026-11-09

  • GU · ProstateRecruitingNot reportedObservationalNCT07052578

    Aggressive Disease Treatment Patterns and CtDNA HRR evaluatiON in High-volume metastatiC hORmone-sensitive Prostate Cancer in Russian FeDeration

    AstraZeneca · 28 locations · Updated 2026-10-22

  • GU · ProstateRecruitingNot reportedObservationalNCT04489719

    Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer

    University of Washington · 4 locations · Updated 2026-10-22

  • GU · ProstateRecruitingNot reportedObservationalNCT07560748

    Prospective Prostate Cancer Infrastructure

    Radboud University Medical Center · 1 locations · Updated 2026-09-10

  • GU · ProstateRecruitingNot reportedObservationalNCT07050433

    COMPASS Study for Metastatic Castration-resistant Prostate Cancer

    Duke University · 4 locations · Updated 2026-08-27

  • GU · Prostate, Bladder / urothelialNot yet recruitingNot reportedObservationalNCT07468838

    Feasibility Study of Urinary cfDNA Analysis as a Non-invasive Monitoring Tool in Patients With Prostate or Bladder Cancer

    Institut Cancerologie de l'Ouest · Locations not reported · Updated 2026-03-16

  • GU · ProstateRecruitingNot reportedObservationalNCT06200974

    Multi-omic Approach to Study HDR Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer

    British Columbia Cancer Agency · 1 locations · Updated 2026-02-02

  • GU · ProstateRecruitingNot reportedObservationalNCT07334275

    Detection of Minimal Residual Disease Post-prostatectomy

    Radboud University Medical Center · 1 locations · Updated 2026-01-12

  • GU · ProstateRecruitingNot reportedObservationalNCT07118436

    Liquid Biopsy Under PSMA Radioligand Therapy

    Wuerzburg University Hospital · 3 locations · Updated 2025-08-12

  • GU · ProstateRecruitingNot reportedObservationalNCT05885009

    Feasibility and Impact of Liquid Biopsy Genomic Profiling on Treatment Patients With Metastatic Prostate Cancer in Spain (SOLTI-2102)

    SOLTI Breast Cancer Research Group · 1 locations · Updated 2025-08-06

  • GU · ProstateRecruitingNot reportedObservationalNCT06949254

    PRospective Observational Study of STereotactic Body rAdiation Therapy With Androgen Deprivation Therapy for Organ-confined High-risk Prostate Cancer: the PROSTAR Trial

    Istituto Clinico Humanitas · 3 locations · Updated 2025-07-30

  • GU · ProstateRecruitingNot applicableNCT06659926

    The Radium-select Study

    The Netherlands Cancer Institute · 5 locations · Updated 2025-07-08

  • GU · ProstateRecruitingNot reportedObservationalNCT06981377

    PRostate Cancer Plasma Integrative Multi-modal Evaluation

    Santa Chiara Hospital · 4 locations · Updated 2025-05-20

  • GU · ProstateRecruitingPhase 1NCT05656573

    CART-PSMA Cells for Advanced Prostate Cancer

    Nova Therapeutics LLC · 1 locations · Updated 2024-11-15

  • GU · Kidney / RCC, Prostate, Bladder / urothelialRecruitingNot reportedObservationalNCT04197414

    Development of Urologic Registry for Personalized Medicine in Patients With Urological Malignancy by Analyzing Circulating Tumor DNA

    Yonsei University · 1 locations · Updated 2019-12-13

Status can change after this sync. The curated list is the other view on this page. Evidence holds the published results.